Keytruda And Opdivo Move Closer To European Marketing Battle
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck & Co has gained its first positive opinion for Keytruda from Europe’s top advisory panel the CHMP, while Bristol-Myers Squibb’s Opdivo has received its second positive opinion, for use in lung cancer.